Atezolizumab

[MAF] Atezolizumab (Tecentriq) Concentrate For Infusion 840 mg/14 mL, 1,200 mg/20 mL

1. Atezolizumab in combination with bevacizumab biosimilar (subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.

2. Atezolizumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer.

3. For untreated metastatic non-small cell lung cancer (NSCLC), in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations.

4. Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.

5. Atezolizumab in combination with bevacizumab biosimilar (subsidised brand) and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.

6. Atezolizumab in combination with platinum-doublet chemotherapy, for untreated metastatic non-squamous non-small cell lung cancer (NSCLC), in patients with no EGFR or ALK genomic tumour aberrations.

7. Adjuvant treatment following complete resection for patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy. Maximum duration of treatment: 12 months.

[MSHL] Atezolizumab Concentrate For Solution For Infusion 840 mg/14 mL, 1,200 mg/20 mL

1. Atezolizumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer.

2. For untreated metastatic non-small cell lung cancer (NSCLC), in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations.

3. Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.

4. Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic UC.

5. Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.

6. Treatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 (PD-L1 stained tumour-infiltrating immune cells covering ≥5% of the tumour area), and who are not eligible for cisplatin-containing chemotherapy.

7. Atezolizumab in combination with platinum-doublet chemotherapy, for untreated metastatic non-squamous non-small cell lung cancer (NSCLC), in patients with no EGFR or ALK genomic tumour aberrations.

8. Adjuvant treatment following complete resection for patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy. Maximum duration of treatment: 12 months.

[MSHL] Atezolizumab Concentrate For Solution For Infusion 840 mg/14 mL, 1,200 mg/20 mL

1. Atezolizumab in combination with bevacizumab (non-subsidised brand) and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.

2. Atezolizumab in combination with bevacizumab (non-subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.

[MSHL] Atezolizumab Concentrate For Solution For Infusion 840 mg/14 mL, 1,200 mg/20 mL

1. Atezolizumab in combination with bevacizumab biosimilar (subsidised brand) and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.

2. Atezolizumab in combination with bevacizumab biosimilar (subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.

[MSHL] Atezolizumab Concentrate For Solution For Infusion 840 mg/14 mL, 1,200 mg/20 mL

1. Atezolizumab in combination with nab-paclitaxel for treating patients with unresectable, locally advanced, or metastatic triple negative breast cancer whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

13/09/2024 Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions

The Ministry of Health’s Drug Advisory Committee has reviewed all available treatments for cancer to update the MOH List of Subsidised Drugs in line with local clinical practice and medical advancements. As part of this review, Technology Guidances have been prepared which describe the subsidy recommendations for many cancer drugs for specific clinical conditions. The remaining treatments which have been considered by the Committee are included in this document.

[R] Based on the available evidence, the Ministry of Health’s Drug Advisory Committee has recommended:

• Abemaciclib 50 mg, 100 mg and 150 mg tablets;

• Abiraterone acetate 250 mg tablets;

• Afatinib 20 mg, 30 mg and 40 mg tablets;

• Alectinib 150 mg capsule;

• Anagrelide 0.5 mg capsule;

• Atezolizumab 840 mg/14 mL and 1200 mg/20 mL concentrate for solution for infusion;

• Avelumab 200 mg/10 mL concentrate for solution for infusion;

• Axitinib 1 mg and 5 mg tablets;

• Azacitidine 100 mg injection;

• Bendamustine 25 mg and 100 mg concentrate for infusion;

• Bicalutamide 50 mg tablet;

• Bortezomib 3.5 mg injection;

• Brentuximab vedotin 50 mg powder for concentrate for solution for infusion;

• Brigatinib 30 mg, 90 mg and 180 mg tablets;

• Cabozantinib 20 mg, 40 mg and 60 mg tablets;

• Ceritinib 150 mg capsule;

• Cetuximab 100 mg/20 mL solution for infusion;

• Cisplatin 100 mg/100 mL concentrate for infusion;

• Cyproterone 50 mg tablet;

• Dabrafenib 50 mg and 75 mg capsules;

• Dasatinib 20 mg, 50 mg and 70 mg tablets;

• Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion;

• Epirubicin 50 mg/25 mL injection;

• Eribulin mesylate 1 mg/2 mL solution for injection;

• Erlotinib 100 mg and 150 mg tablets;

• Exemestane 25 mg tablet;

• Fludarabine phosphate 50 mg injection;

• Fulvestrant 250 mg/5 mL solution for injection;

• Gefitinib 250 mg tablet;

• Gilteritinib fumarate 40 mg tablet;

• Goserelin 3.6 mg and 10.8 mg depot injections;

• Imatinib 100 mg and 400 mg tablets;

• Ipilimumab 50 mg/10 mL concentrate for solution for infusion;

• Lapatinib 250 mg tablets;

• Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules;

• Leuprorelin acetate 3.75 mg and 11.25 mg depot injection;

• Lorlatinib 25 mg and 100 mg tablets;

• Megestrol 40 mg and 160 mg capsules;

• Midostaurin 25 mg capsule;

• Nilotinib 50 mg, 150 mg and 200 mg capsules;

• Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion;

• Obinutuzumab 1000 mg/40 mL concentrate for solution for infusion;

• Olaparib 100 mg and 150 mg tablets;

• Oxaliplatin 200 mg/40 mL concentrate for infusion;

• Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension;

• Palbociclib 75 mg, 100 mg and 125 mg capsules/tablets;

• Pazopanib 200 mg and 400 mg tablets;

• Pegylated liposomal doxorubicin 20 mg concentrate for infusion;

• Pembrolizumab 100 mg/4 mL solution for infusion;

• Pemetrexed 100 mg and 500 mg injections;

• Ponatinib 15 mg tablet;

• Ribociclib 200 mg tablet;

• Ruxolitinib 5 mg, 15 mg and 20 mg tablets;

• Somatropin 5 mg/1.5 mL and 10 mg/1.5 mL prefilled pens and solution for injection;

• Somatropin 4 mg and 5.3 mg/mL powder and solvent for solution for injection;

• Somatropin 5.83 mg/mL and 8 mg/mL solution for injection;

• Sunitinib 12.5 mg capsules;

• Trametinib 0.5 mg and 2 mg tablets; and

• Vinorelbine 50 mg/5 mL injection

for inclusion on the MOH Standard Drug List (SDL) or Medication Assistance Fund (MAF) in line with their registered indications or specific clinical criteria for treating cancer, in view of clinical need, and acceptable clinical and cost effectiveness.

[NR] Drugs that have not been recommended for subsidy are listed in the Annex.

For all drugs, the clinical indications, subsidy class, subsidy implementation dates (if applicable), and MediShield Life claim limits are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration